Last mentioned: Mar 25, 2026
Potential EU Launch
Target window for commercial availability of iopofosine I 131 in Europe.
EMA Submission
Planned filing of Conditional Marketing Authorization for iopofosine I 131.
CLR 125 Data
Expected early data readout from Phase 1b study in triple-negative breast cancer.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Financial Results
Company reports 2025 results and provides corporate update.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
Fiscal Year End
Cellectar completes a year of pipeline advancement and platform validation.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.
This page surfaces every story mentioning U.S. Food and Drug Administration across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where U.S. Food and Drug Administration was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |